16.06.2023 MediClin AG  DE0006595101

EQS-News: MediClin AG: MEDICLIN focusses on innovative outpatient concepts in rehabilitation


 

EQS-News: MediClin AG / Key word(s): AGM/EGM
MediClin AG: MEDICLIN focusses on innovative outpatient concepts in rehabilitation

16.06.2023 / 12:15 CET/CEST
The issuer is solely responsible for the content of this announcement.


MEDICLIN focusses on innovative outpatient concepts in rehabilitation

At yesterday's General Annual Meeting of MEDICLIN Aktiengesellschaft (MEDICLIN), the chairman of the Management Board, Dr. Joachim Ramming, explained his contentedness with the past financial year 2022 thanks to increased sales in the Group and an improved Group operating result compared to the previous year.

But he also emphasized: "It wasn't just the higher capacity utilisation figures, but also our stringent cost control. As a result, we were able to absorb at least part of the cost increases caused by the geopolitical general conditions in 2022.”

The healthcare industry is facing major challenges

As far as the business development of the current financial year is concerned, the Management Board is satisfied with the development of capacity utilisation, but expressly referred to the current challenges, in particular the shortage of skilled workers. Tino Fritz, CFO of MEDICLIN, said: “One of the challenges is the reforms that have been passed or are being discussed in the healthcare system. They essentially affect the acute sector and thus part of our business but will also have an impact on the rehabilitation sector and thus on our largest segment.”

Sustainable concepts in rehabilitation

Dr. York Dhein, Member of the Management Board, whose responsibilities include the rehabilitation segment, sees opportunities here: "We see two developments: on the one hand, an increasing demand for more outpatient and digitally supported offers and, on the other hand, an increasing need for inpatient rehabilitation near home and in the same clinic, in where the acute treatment has already taken place - the keywords here are a continuous care process and quality assurance. Good opportunities to make our core competence rehabilitation fit for the future.”

Portfolio adjustments to the structural changes in the healthcare market

"The diverse changes in our market require a flexible handling of our skills and the determination of new application possibilities," explained Dr. Ramming. In its core business, rehabilitation, MEDICLIN will develop new offers and become more flexible, more outpatient and more digital.

In the acute segment, it will be a matter of thinking about changes in the range of services, cooperation and, if necessary, portfolio changes in order to be able to ensure comprehensive acute care with high medical quality in a region at the same time.

Information on the Annual General Meeting

At the Annual General Meeting of MEDICLIN Aktiengesellschaft, 92.83% of the share capital was represented. The actions of the Management Board and the Supervisory Board for 2022 were approved with majorities of 98.06% and 97.96% respectively. With a large majority of 96.70%, the Annual General Meeting approved the remuneration report for the Management Board and the Supervisory Board. The Annual General Meeting took place as a face-to-face event in Offenburg, the company’s registered office.

 

About MEDICLIN

MEDICLIN includes 32 clinics, six care facilities and ten medical care centres. The Group has around 8,300 beds/care places and employs around 10,000 people. In a strong network, MEDICLIN offers the patient integrative care from the first visit to the doctor through the operation and subsequent rehabilitation to outpatient aftercare. Doctors, therapists and nurses work together in a carefully coordinated manner. MEDICLIN designs the care and support of people in need of care according to their individual needs and personal needs.

MEDICLIN ─ a company of the Asklepios Group. www.mediclin.de



16.06.2023 CET/CEST Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.eqs-news.com


Language: English
Company: MediClin AG
Okenstraße 27
77652 Offenburg
Germany
Phone: +49 (0)781 488-326
Fax: +49 (0)781 488-184
E-mail: [email protected]
Internet: www.mediclin.de
ISIN: DE0006595101
WKN: 659510
Listed: Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Munich, Stuttgart, Tradegate Exchange
EQS News ID: 1659325

 
End of News EQS News Service

1659325  16.06.2023 CET/CEST

fncls.ssp?fn=show_t_gif&application_id=1659325&application_name=news&site_id=boersengefluester_html


Die wichtigsten Finanzdaten auf einen Blick
  2017 2018 2019 2020 2021 2022 2023
Umsatzerlöse1 609,08 645,11 673,09 659,86 673,14 704,70 730,07
EBITDA1,2 27,01 37,35 93,58 77,50 85,22 90,92 98,73
EBITDA-Marge3 4,43 5,79 13,90 11,74 12,66 12,90
EBIT1,4 6,62 15,06 22,41 0,15 11,56 19,52 12,72
EBIT-Marge5 1,09 2,33 3,33 0,02 1,72 2,77 1,74
Jahresüberschuss1 3,96 7,76 9,68 -0,04 1,49 9,72 -10,72
Netto-Marge6 0,65 1,20 1,44 -0,01 0,22 1,38 -1,47
Cashflow1,7 19,34 29,77 69,59 118,69 81,97 34,64 78,00
Ergebnis je Aktie8 0,08 0,16 0,20 -0,19 0,03 0,20 -0,23
Dividende8 0,05 0,05 0,05 0,00 0,00 0,00 0,00
Quelle: boersengefluester.de und Firmenangaben

  Geschäftsbericht 2023 - Kostenfrei herunterladen.  
1 in Mio. Euro; 2 EBITDA = Ergebnis vor Zinsen, Steuern und Abschreibungen; 3 EBITDA in Relation zum Umsatz; 4 EBIT = Ergebnis vor Zinsen und Steuern; 5 EBIT in Relation zum Umsatz; 6 Jahresüberschuss (-fehlbetrag) in Relation zum Umsatz; 7 Cashflow aus der gewöhnlichen Geschäftstätigkeit; 8 in Euro; Quelle: boersengefluester.de

Wirtschaftsprüfer: PricewaterhouseCoopers

INVESTOR-INFORMATIONEN
©boersengefluester.de
Mediclin
WKN Kurs in € Einschätzung Börsenwert in Mio. €
659510 2,600 Halten 123,50
KGV 2025e KGV 10Y-Ø BGFL-Ratio Shiller-KGV
10,00 19,19 0,52 19,55
KBV KCV KUV EV/EBITDA
0,63 1,58 0,17 1,45
Dividende '22 in € Dividende '23 in € Div.-Rendite '23
in %
Hauptversammlung
0,00 0,00 0,00 06.06.2024
Q1-Zahlen Q2-Zahlen Q3-Zahlen Bilanz-PK
02.05.2025 31.07.2024 04.11.2024 28.03.2025
Abstand 60Tage-Linie Abstand 200Tage-Linie Performance YtD Performance 52 Wochen
7,08% 1,48% -5,11% -1,52%
    
Weitere Ad-hoc und Unternehmensrelevante Mitteilungen zu MediClin AG  ISIN: DE0006595101 können Sie bei EQS abrufen


Pflegeeinrichtungen , 659510 , MED , XETR:MED